AIM ImmunoTech Inc. (AIM) News
Filter AIM News Items
AIM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AIM News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest AIM News From Around the Web
Below are the latest news stories about AIM IMMUNOTECH INC that investors may wish to consider to help them evaluate AIM as an investment opportunity.
AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsA Plan for Compliance has been UndertakenOCALA, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated December 11, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. This is an issue previously disclosed in our most recent Report on Form 10-Q. Specifically, the letter states |
AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual MeetingOCALA, Fla., December 17, 2024--AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that, based on the preliminary vote count of its proxy solicitor, shareholders have elected three of the Company’s incumbent directors – Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell – to the Board of Directors (the "Board") at the 2024 Annual Meeting of Stockholders (the "Annual Meeting") held today. Additionally, Ted D. Kellner was elected to the Board. |
AIM ImmunoTech Reminds Shareholders to Vote "FOR" All Four Incumbent Board Members on the WHITE Universal Proxy CardOCALA, Fla., December 16, 2024--AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stockholders (the "Annual Meeting"), presently scheduled for December 17, 2024 at 11:00 a.m. ET: |
Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent BoardVote “FOR” All Four Kellner Group Nominees Today on Gold Card for Urgently Needed Change Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 14, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the “Kellner Group,” “we” or “us” and, as nominees, the “Kellner Group Nominees”), issues this urgent statement in respons |
UPDATE: Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold CardIncumbent Board has Destroyed Stockholder Value and Imperiled AIM’s Future through Breaches of Fiduciary Duty and Bad Faith Actions Stock Price has Declined by More than 99%, Clinical Strategy has Failed and AIM is on the Brink of Insolvency Act Now to Save AIM Before it is Too Late – The Kellner Group Can Turn AIM Around and Finally Start Creating Value for Stockholders Vote “FOR” All Four Kellner Group Nominees for Urgently Needed Change Kellner Group Owns 5.04% of Outstanding Shares and is Fu |
AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board MembersOCALA, Fla., December 12, 2024--AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today issued the following statement in connection with the upcoming 2024 Annual Meeting of Stockholders (the "Annual Meeting"), presently scheduled for December 17, 2024: |
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of FatigueOCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has granted Patent No. 2,032,813 — a compositions and methods patent — covering Ampligen® (rintatolimod) for use in the treatment of the post-COVID condition of fatigue. The patent inventors, AIM CEO Thomas K. Equels and AIM Medical Officer David R. Strayer, M.D., have assigned the granted patent to the Comp |
Kellner Group Announces Support from Another Former AIM Senior ExecutiveFollows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner Group Nominees Are Elected Kellner Group Reiterates Plan to Revitalize AIM, Accelerate Clinical Development and Restore Value for StockholdersKellner Group Urges Stockholders of AIM Immunotech to Vote the Gold Card Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with Stockholders NEW YORK, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Ted Kellner, as the |
AIM’s Clinical Strategy Under Incumbent Board Has Totally FailedIncumbent Board’s Claims of Progress Are Not Credible or Supported by DataAIM Maintains Relationship with CRO Co-Founded by a Convicted Felon Who Deceived Investors about the Timeline and Status of Regulatory Submissions to the U.S. FDAAccording to ISS – “The lack of transparency gives the impression that the company’s pipeline is more advanced and that the company is more involved than it actually is”1 Kellner Group Owns 5.04% of Outstanding Shares and is Fully Aligned with StockholdersKellner |
Glass Lewis Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. MitchellOCALA, Fla., December 10, 2024--AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that independent proxy advisory firm Glass, Lewis & Co., LLC ("Glass Lewis") has recommended that shareholders vote "FOR" Company nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell at the upcoming 2024 Annual Meeting of Stockholders (the "Annual Meeting"), presently scheduled for December 17, 2024. |